<< Back To Search

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
In simple words, scientists are studying a new medicine called PHE885 to treat a type of cancer called multiple myeloma. The medicine is made in a special way and researchers want to see if it works well and is safe to use. They will test it on patients who have had the cancer come back after treatment or who did not respond to treatment before.
*Third Opinion AI Generated Synopsis

Trial Summary
This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?